BRÈVE

sur Relief Therapeutics Holdings AG (NASDAQ:RLFTF)

RELIEF THERAPEUTICS Holding SA Announces Extraordinary General Meeting for Anticipated Corporate Changes

RELIEF THERAPEUTICS Holding SA has scheduled an extraordinary general meeting (EGM) for its shareholders, set to take place on April 26, 2024, at 03:00 p.m. CEST. The meeting will focus on significant corporate changes, including the election of three new members to the Board of Directors, adjustments to share capital, and amendments to align with the new corporate law. This move, supported by the Company’s largest shareholder, aims to enhance flexibility for future financial and business opportunities.

The shareholders will vote on several key agenda items, such as the induction of Peter de Svastich, Gregory Van Beek, and Thomas Elzinga to the Board. These nominations come from Global Emerging Markets (GEM), holding a substantial share of the Company’s capital. The agenda also proposes a technical adjustment to reduce the nominal value of company shares, maintaining shareholder rights while enabling capital raise flexibility. Furthermore, plans to reinstate and extend the Company's capital band and increase conditional share capital will be tabled, aiming to support future financing and business decisions.

The EGM will also involve votes on executive and Board compensation and the discharge of existing Board and Executive Committee members concerning their service in recent financial years. These proposals follow Swiss corporate law practices and aim to align executive interests with shareholder value.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Relief Therapeutics Holdings AG